NHS England unveils new Innovative Medicines Fund

NHS England has launched its new Innovative Medicines Fund (IMF). This fund is for the early access to ‘potentially life-saving’ new treatments, and builds upon the current Cancer Drugs Fund (CDF). The IMF will be used to fast-track promising new drugs to patients with any condition, including those with rare and genetic diseases, who need […]

read more

The link between physical exercise and cancer

Physical activity has many benefits, including increasing the chance of living a healthy life beyond retirement, lowering the risk of being overweight, improving mental health, and lowering the risk for various diseases, including cancer. Various observational studies, a type of study in which individuals are observed or certain outcomes are measured, have shown that leisure-time […]

read more

Open letter from cancer charities to the public

Forty (40) charities and organisations have written an open letter, urging the public to help keep vulnerable people safe as restrictions ease. Rose Woodward, Founder and Patient Advocate of KCSN, was one of those who endorsed this letter. The letter was published in The Guardian yesterday: Here is the letter in full: Tomorrow in England […]

read more

Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer

This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC). There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused […]

read more

Positive margins after partial nephrectomy and risk of recurrence in kidney cancer

In this meta-analysis, the results from 101,153 patients with renal cell carcinoma (RCC) from 42 studies were assessed for the risk of recurrence in patients with positive margins after partial nephrectomy (nephron-sparing surgery). The analysis showed that a positive surgical margin was associated with an increased risk of local recurrence (high certainty), metastasis (moderate certainty), […]

read more

ARO-HIF2 shows promise for advanced kidney cancer

A small phase 1b study of a new medicine called ARO-HIF2 has shown promise for the treatment of people with advanced clear cell renal cell carcinoma (RCC). Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF2. This results […]

read more
Showing 1 to 6 of 1110 results